WO2007102606A1 - 足場材料 - Google Patents
足場材料 Download PDFInfo
- Publication number
- WO2007102606A1 WO2007102606A1 PCT/JP2007/054739 JP2007054739W WO2007102606A1 WO 2007102606 A1 WO2007102606 A1 WO 2007102606A1 JP 2007054739 W JP2007054739 W JP 2007054739W WO 2007102606 A1 WO2007102606 A1 WO 2007102606A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- scaffold material
- fiber
- fibers
- material according
- scaffold
- Prior art date
Links
- 239000000463 material Substances 0.000 title claims abstract description 133
- 239000000835 fiber Substances 0.000 claims abstract description 112
- 229920000249 biocompatible polymer Polymers 0.000 claims abstract description 21
- 239000000758 substrate Substances 0.000 claims abstract description 6
- 238000004113 cell culture Methods 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 38
- 238000004804 winding Methods 0.000 claims description 31
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 230000005686 electrostatic field Effects 0.000 claims description 9
- 229920001577 copolymer Polymers 0.000 claims description 8
- 229920003232 aliphatic polyester Polymers 0.000 claims description 6
- 230000001172 regenerating effect Effects 0.000 claims description 5
- 229920000747 poly(lactic acid) Polymers 0.000 claims description 4
- 239000004626 polylactic acid Substances 0.000 claims description 4
- 230000002062 proliferating effect Effects 0.000 claims description 4
- 229920000954 Polyglycolide Polymers 0.000 claims description 2
- 239000004633 polyglycolic acid Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 26
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- -1 etc.) Substances 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000002904 solvent Substances 0.000 description 12
- 230000010261 cell growth Effects 0.000 description 10
- 239000011148 porous material Substances 0.000 description 10
- 238000000151 deposition Methods 0.000 description 9
- 229920000642 polymer Polymers 0.000 description 9
- 230000008021 deposition Effects 0.000 description 8
- 238000009987 spinning Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000006835 compression Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 238000001523 electrospinning Methods 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000001788 irregular Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 238000012925 biological evaluation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000011147 inorganic material Substances 0.000 description 3
- 229960000448 lactic acid Drugs 0.000 description 3
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 230000003068 static effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 description 2
- 102000015336 Nerve Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 150000005215 alkyl ethers Chemical class 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 239000002543 antimycotic Substances 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005421 electrostatic potential Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 229910010272 inorganic material Inorganic materials 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 229940053128 nerve growth factor Drugs 0.000 description 2
- 239000004745 nonwoven fabric Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000011368 organic material Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 229920001308 poly(aminoacid) Polymers 0.000 description 2
- 229920002635 polyurethane Polymers 0.000 description 2
- 239000004814 polyurethane Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003431 steroids Chemical class 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- FPJHWYCPAOPVIV-VOZMEZHOSA-N (2R,3S,4R,5R,6R)-6-[(2R,3R,4R,5R,6R)-5-acetamido-2-(hydroxymethyl)-6-methoxy-3-sulfooxyoxan-4-yl]oxy-4,5-dihydroxy-3-methoxyoxane-2-carboxylic acid Chemical compound CO[C@@H]1O[C@H](CO)[C@H](OS(O)(=O)=O)[C@H](O[C@@H]2O[C@H]([C@@H](OC)[C@H](O)[C@H]2O)C(O)=O)[C@H]1NC(C)=O FPJHWYCPAOPVIV-VOZMEZHOSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- VPVXHAANQNHFSF-UHFFFAOYSA-N 1,4-dioxan-2-one Chemical compound O=C1COCCO1 VPVXHAANQNHFSF-UHFFFAOYSA-N 0.000 description 1
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 1
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007710 Cartilage injury Diseases 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 229920002558 Curdlan Polymers 0.000 description 1
- 239000001879 Curdlan Substances 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- WDJUZGPOPHTGOT-OAXVISGBSA-N Digitoxin Natural products O([C@H]1[C@@H](C)O[C@@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@@](C)([C@H](C6=CC(=O)OC6)CC5)CC4)CC3)CC2)C[C@H]1O)[C@H]1O[C@@H](C)[C@H](O[C@H]2O[C@@H](C)[C@@H](O)[C@@H](O)C2)[C@@H](O)C1 WDJUZGPOPHTGOT-OAXVISGBSA-N 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 241000543370 Galax Species 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- ACFGRWJEQJVZTM-LEJBHHMKSA-L Magnesium L-ascorbic acid-2-phosphate Chemical class [Mg+2].OC[C@H](O)[C@H]1OC(=O)C(OP([O-])([O-])=O)=C1O ACFGRWJEQJVZTM-LEJBHHMKSA-L 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 108010072582 Matrilin Proteins Proteins 0.000 description 1
- 102000055008 Matrilin Proteins Human genes 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- ZYFVNVRFVHJEIU-UHFFFAOYSA-N PicoGreen Chemical compound CN(C)CCCN(CCCN(C)C)C1=CC(=CC2=[N+](C3=CC=CC=C3S2)C)C2=CC=CC=C2N1C1=CC=CC=C1 ZYFVNVRFVHJEIU-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920000805 Polyaspartic acid Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 108010020346 Polyglutamic Acid Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 241000425571 Trepanes Species 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 229920002000 Xyloglucan Polymers 0.000 description 1
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940023476 agar Drugs 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- 229940059329 chondroitin sulfate Drugs 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000007334 copolymerization reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000019316 curdlan Nutrition 0.000 description 1
- 229940078035 curdlan Drugs 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229960002086 dextran Drugs 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 150000001982 diacylglycerols Chemical class 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- WDJUZGPOPHTGOT-XUDUSOBPSA-N digitoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)CC5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O WDJUZGPOPHTGOT-XUDUSOBPSA-N 0.000 description 1
- 229960000648 digitoxin Drugs 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- WQLVFSAGQJTQCK-UHFFFAOYSA-N diosgenin Natural products CC1C(C2(CCC3C4(C)CCC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 WQLVFSAGQJTQCK-UHFFFAOYSA-N 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 239000002019 doping agent Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 238000010041 electrostatic spinning Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000002657 fibrous material Substances 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000012212 insulator Substances 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 239000002121 nanofiber Substances 0.000 description 1
- 229920005615 natural polymer Polymers 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002463 poly(p-dioxanone) polymer Polymers 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 108010064470 polyaspartate Proteins 0.000 description 1
- 229920002961 polybutylene succinate Polymers 0.000 description 1
- 239000004631 polybutylene succinate Substances 0.000 description 1
- 239000000622 polydioxanone Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002643 polyglutamic acid Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- NWMIYTWHUDFRPL-UHFFFAOYSA-N sapogenin Natural products COC(=O)C1(CO)C(O)CCC2(C)C1CCC3(C)C2CC=C4C5C(C)(O)C(C)CCC5(CCC34C)C(=O)O NWMIYTWHUDFRPL-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 238000004154 testing of material Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 229950003937 tolonium Drugs 0.000 description 1
- HNONEKILPDHFOL-UHFFFAOYSA-M tolonium chloride Chemical compound [Cl-].C1=C(C)C(N)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 HNONEKILPDHFOL-UHFFFAOYSA-M 0.000 description 1
- 150000004992 toluidines Chemical class 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- HFQKBOPMAOTAIR-TZSVBWBLSA-N α-d-galactosyl-(1->4)-β-d-galactosyl-(1->4)-β-d-glucosylceramide Chemical compound O[C@@H]1[C@@H](O)[C@H](OC[C@@H]([C@H](O)/C=C/CCCCCCCCCCCCC)NC(C)=O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1 HFQKBOPMAOTAIR-TZSVBWBLSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
- C12M25/00—Means for supporting, enclosing or fixing the microorganisms, e.g. immunocoatings
- C12M25/14—Scaffolds; Matrices
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
- C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
- C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
- D01D5/00—Formation of filaments, threads, or the like
- D01D5/0007—Electro-spinning
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/02—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D01F6/04—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polyolefins
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/02—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D01F6/20—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of cyclic compounds with one carbon-to-carbon double bond in the side chain
- D01F6/22—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolymers obtained by reactions only involving carbon-to-carbon unsaturated bonds from polymers of cyclic compounds with one carbon-to-carbon double bond in the side chain from polystyrene
-
- D—TEXTILES; PAPER
- D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
- D01F—CHEMICAL FEATURES IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS; APPARATUS SPECIALLY ADAPTED FOR THE MANUFACTURE OF CARBON FILAMENTS
- D01F6/00—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof
- D01F6/58—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products
- D01F6/66—Monocomponent artificial filaments or the like of synthetic polymers; Manufacture thereof from homopolycondensation products from polyethers
-
- D—TEXTILES; PAPER
- D04—BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
- D04H—MAKING TEXTILE FABRICS, e.g. FROM FIBRES OR FILAMENTARY MATERIAL; FABRICS MADE BY SUCH PROCESSES OR APPARATUS, e.g. FELTS, NON-WOVEN FABRICS; COTTON-WOOL; WADDING ; NON-WOVEN FABRICS FROM STAPLE FIBRES, FILAMENTS OR YARNS, BONDED WITH AT LEAST ONE WEB-LIKE MATERIAL DURING THEIR CONSOLIDATION
- D04H3/00—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length
- D04H3/02—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments
- D04H3/07—Non-woven fabrics formed wholly or mainly of yarns or like filamentary material of substantial length characterised by the method of forming fleeces or layers, e.g. reorientation of yarns or filaments otherwise than in a plane, e.g. in a tubular way
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/30—Synthetic polymers
- C12N2533/40—Polyhydroxyacids, e.g. polymers of glycolic or lactic acid (PGA, PLA, PLGA); Bioresorbable polymers
Definitions
- the present invention relates to a scaffold material used for cell growth.
- the present invention relates to a scaffold material comprising an assembly of fibers and suitable for a prosthetic material or a cell culture substrate.
- the extracellular matrix functions as a scaffold and constructs tissues.
- the scaffold material prosthetic material
- the properties required for this scaffold material include 1) bioabsorbability, 2) cell adhesion, 3) porosity, 4) mechanical strength and the like.
- synthetic polymers polyglycolic acid, polylactic acid, polystrength prolacton, etc.
- natural polymers collagen, gelatin, elastin, hyaluronic acid, algin
- Acid chitosan, etc.
- inorganic materials hydroxypatite,] 8-tricalcium phosphate
- porosity As mentioned above, one of the important properties required for scaffold materials (prosthetic materials) is porosity. This is important in terms of providing sufficient oxygen and nutrients to the cells necessary to regenerate the tissue and expelling carbon dioxide and waste products quickly. For this reason, freeze-drying methods, phase separation methods, foaming methods, etc. have been proposed in order to achieve the porosity of the scaffold material.
- the structure obtained by the freeze-drying method or the phase separation method has a pore-like shape, which makes it difficult for cells to invade and has an unsatisfactory problem as a scaffold material.
- the structure obtained by the foaming method has pores alone, so that cells can enter the structure. There is a problem that it is difficult.
- Non-patent Document 1 it has been proposed to produce a scaffold material in which nanofibers are deposited in a planar shape by an electrospinning method, and to culture cells using this scaffold material.
- the fibers are collected on a flat collecting electrode, so if the fibers are deposited to a certain thickness or more, the electrodes are covered with deposits, making it difficult to maintain a constant potential difference.
- the density force of fiber deposits s has the disadvantage of changing in the direction of deposition.
- deposits are uneven in the deposition density even in the plane direction perpendicular to the deposition direction. Therefore, in order to use this deposit as a scaffold for cell growth, it is necessary to make the deposition density uniform and improve the mechanical strength.
- Patent Document 1 WO 2 0 0 4/8 8 0 2 4
- Patent Document 2 (Patent Document 2) Special Table 2 0 0 4— 5 2 0 8 5 5
- Non-Patent Document 1 Publ ished online 25 March 2002 in Wiley InterScience (www.interscience.wiley.com) Disclosure of Invention
- An object of the present invention is to provide a scaffold material suitable for cell growth in which fibers are gathered at a high density.
- An object of the present invention is to provide a scaffold material for cell growth having excellent mechanical strength.
- An object of the present invention is to provide a scaffold material capable of favorably growing cells.
- Another object of the present invention is to provide a method for producing the scaffold material.
- an object of the present invention is to provide a method for proliferating cells using the scaffold material. To provide a law.
- Another object of the present invention is to provide a method for regenerating a living tissue using the scaffold material.
- the present inventor has found that when a fiber is produced by an electrospinning method and the obtained fiber is deposited on a rotating winding shaft, a fiber deposit having a uniform deposition density in the deposition direction can be obtained.
- the obtained fiber deposit was found to have an appropriate strength and fiber density as a scaffold material for cell growth.
- the present invention is based on these findings.
- the present invention comprises a three-dimensional structure composed of an aggregate of fibers, composed of two bottom surfaces and side surfaces,
- the diameter of the fiber is 0.05-50 ⁇
- the fibers are mainly composed of biocompatible polymers
- the present invention also provides: (1) A dope containing a biocompatible polymer is ejected from a nozzle in an electrostatic field formed between electrodes to form fibers;
- the present invention includes a method of dividing and proliferating cells using the scaffold material. Also included is a method of regenerating biological tissue by implanting the scaffold material into a damaged affected area.
- Fig. 1 An example of an apparatus used in the electrospinning method.
- Fig. 2 An example of an apparatus used in the electrospinning method.
- Fig. 3 An example of a device used in the antistatic method.
- Fig. 4 shows an example of a device used in the antistatic method.
- FIG. 5 shows an example of a method for cutting out a scaffold material in the production method of the present invention.
- FIG. 6 is an upper bottom image of the scaffold material obtained in Example 2.
- FIG. 7 is a lower bottom image of the scaffold material obtained in Example 2.
- FIG. 8 is a stained image of the first day of culture using the scaffold material in Example 2.
- FIG. 9 is a stained image of the first day of culture 1 using the scaffold material in Example 2.
- FIG. 10 is an upper bottom image of the scaffold material obtained in Example 3.
- FIG. 1 1 is a lower bottom image of the scaffold material obtained in Example 3.
- FIG. 12 is an example of a cross-sectional image of the scaffold material obtained in Example 3.
- FIG. 1 3 is a stained image of the first day of culture using the scaffold material in Example 3.
- FIG. 14 is a stained image of culture on day 1 using the scaffold material in Example 3.
- the scaffold material of the present invention has a three-dimensional structure composed of two bottom surfaces and side surfaces.
- the shape of the bottom can be any shape such as a circle, ellipse, or rectangle.
- the bottom surface may be an uneven curved surface.
- the shape and size of the two bottom surfaces may be different.
- the area of the bottom surface is preferably 0 0 5 to 8 cm 2, more preferably 0 1: a L cm 2...
- the side surface may be a continuous curved surface or a plurality of surfaces. That is, the shape of the scaffold material of the present invention is preferably a three-dimensional structure such as a cylindrical body or a polygonal column.
- the scaffold material of the present invention has a three-dimensional structure, that is, a lateral direction (X axis), a longitudinal direction (y axis), and a height direction (z axis). In this respect, it is different from a planar nonwoven fabric having a spread in the horizontal direction (X axis) and the vertical direction (y axis).
- the height direction means a direction perpendicular to one bottom surface.
- the height of the scaffold material is preferably 0.5 mm or more, more preferably 2 mm or more. Regardless of the upper limit of the height, it can be said that it depends on the site used as the prosthetic material. If the height is less than 0.5 mm, the mechanical strength is low, and it is not preferable as a prosthetic material for tissues with high loads such as knee joints.
- the scaffold material of the present invention can be used, for example, to be embedded in a damaged part of a living body and to proliferate cells on the surface of the prosthesis. Scaffolding material can be provided in any desired shape.
- the scaffold material of the present invention comprises an aggregate of fibers.
- the orientation in the plane direction means that the fibers are oriented substantially parallel to a specific plane. As long as the fiber is parallel to this specific plane, the fiber may be oriented in any of the lateral direction, the longitudinal direction, and the oblique direction.
- the fibers are oriented substantially parallel to the plane indicated by the broken line in the cylindrical body indicated by 10 or 12 in FIG. Further, the dotted line portion shown in 10 or 12 of FIG. 5 may form a concentric curved surface.
- the orientation of the fibers on the plane is random.
- the fibers are preferably oriented in a plane direction parallel to the height direction as indicated by 10 in FIG. Or, as shown in Fig. 5, 1 2, the fibers are perpendicular to the height direction. It is preferable to be oriented in the direction.
- the diameter of the fiber is 0.05 to 5 0. If the fiber diameter is smaller than 0.05 m, the strength of the scaffold material cannot be maintained, which is not preferable. On the other hand, when the fiber diameter is larger than 50 m, the specific surface area of the fiber is small and the number of engrafted cells is reduced.
- the diameter of the fiber is preferably 0.2 to 50 m, more preferably 0.2 to 40 mm. The diameter of the fiber can be determined by observing the scaffold material with, for example, a scanning electron microscope (magnification of about 200 times).
- the arbitrary cross section of the fiber may be a substantially perfect circle or an irregular shape. If the cross section of an arbitrary fiber is irregular, the specific area of the fiber increases, so that a sufficient area for the cell to adhere to the fiber surface can be taken during cell culture.
- an arbitrary cross section of the fiber is an irregular shape refers to any shape in which the arbitrary cross section of the fiber does not take a substantially circular shape, and the fiber surface has a uniform recess and / or protrusion. And the case where it is roughened.
- the irregular shape includes fine concave portions on the fiber surface, fine convex portions on the fiber surface, concave portions formed in a streak shape in the fiber axis direction on the fiber surface, convex portions formed in a streaky shape in the fiber axis direction on the fiber surface and It is preferable to use at least one selected from the group consisting of fine pores on the fiber surface, and these may be formed singly or in combination.
- the above-mentioned “fine concave portions” and “fine convex portions” mean that 0.1 to lm concave portions or convex portions are formed on the fiber surface, and “fine pores” means , 0.1 to 1 zm of the pores are present on the fiber surface.
- the concave portion and the Z or convex portion formed in the above-described streak shape means that a hook shape having a width of 0.1 to 1 m is formed in the fiber axis direction.
- Apparent density of the scaffold is, 9 5 ⁇ 3 5 0 kg / m 3, preferably 1 0 0 ⁇ 3 0 0 kg / m 3, more preferably 1 0 0 ⁇ 2 5 0 k gZm 3 .
- Low and enteroinvasive than the apparent density of 9 5 kg / m 3 has a low mechanical strength of the good ones. If it is higher than 3500 kg Zm 3, it is difficult for cells to enter, and the preferred apparent density as a scaffold material is calculated by measuring the volume (area X height) and mass of the obtained aggregate. can do.
- scaffold materials When scaffold materials are used for transplantation, they must have mechanical strength that can withstand weight compression in the initial stage of transplantation.
- Shape stability against compression can be imparted by directing the fiber orientation direction of the scaffold material of the present invention in the weighted compression direction.
- the compression elasticity of the scaffold material of the present invention is preferably 0.5 MPa to 5 MPa, more preferably 1.5 MPa to 5 MPa.
- the porosity of the scaffold material of the present invention is preferably 75 to 90%, more preferably 78 to 88%.
- the porosity is determined by the ratio of the volume of the porous material minus the volume of the polymer.
- the fibers constituting the scaffold material of the present invention are mainly composed of a biocompatible polymer.
- the fiber is preferably composed of 80 to 100 mol% of repeating units, more preferably 90 to 100 mol% of repeating units derived from biocompatible monomers.
- biocompatible monomers include glycolic acid, lactic acid, force prolactone, and dioxanone. It may also be a blend of biocompatible polymers.
- the biocompatible polymer is preferably a bioabsorbable polymer.
- the bioabsorbable polymer is preferably mainly composed of an aliphatic polyester.
- the aliphatic polyester include polydaricholic acid, polylactic acid, poly force prolactone, polydioxanone, polytrimethylene carbonate, polybutylene succinate, polyethylene succinate, and copolymers thereof.
- the aliphatic polyester is preferably at least one selected from the group consisting of polydaricholic acid, polylactic acid, polystrength prolacton, and copolymers thereof.
- a copolymer of lactic acid and glycolic acid is preferred.
- biocompatible polymers such as polyester, nylon, polysulfone, polyurethane, polyethylene, polypropylene, polymethyl methacrylate, polyhydroxychetyl methacrylate, polychlorinated vinyl, and polysiloxane are also available. It can be used as a polymer constituting the porous body.
- the intrinsic viscosity of the biocompatible polymer is from 0.1 to: I .4 d LZ g, preferably 0.0. 4-1.3 d LZ g, more preferably 0.6-1.2 d LZ g (30 ° C., hexafluoroisopropanol).
- the scaffold material of the present invention may further contain a second component other than the biocompatible polymer.
- the ingredients include phospholipids, carbohydrates, glycolipids, steroids, polyamino acids, proteins, and polyoxyalkylenes, FGF (fibroblast growth factor), EGF (epidermal growth factor), PDGF (Platelet-derived growth factor), TGF—; 6 (; 6 type transforming growth factor), NGF (nerve growth factor), HG F (hepatocyte growth factor), BMP (bone morphogenetic factor) and other cell growth factors
- FGF fibroblast growth factor
- EGF epidermal growth factor
- PDGF Platinum-derived growth factor
- TGF— fibroblast growth factor
- 6 6 type transforming growth factor
- NGF nerve growth factor
- HG F hepatocyte growth factor
- BMP bone morphogenetic factor
- the scaffold material of the present invention can be produced by the first to third steps.
- the first step is the so-called electrospinning method.
- the first step is a step in which a fiber containing a biocompatible polymer is discharged from a nozzle in an electrostatic field formed between electrodes to form fibers.
- the electrostatic field is formed between a pair or a plurality of electrodes.
- the electrode may be any metal, inorganic, or organic material that exhibits electrical conductivity.
- a thin film of a metal, an inorganic material, or an organic material exhibiting conductivity may be provided over an insulator.
- a high voltage may be applied to any electrode. This includes, for example, the case of using a total of three electrodes, one with high voltage (for example, 15 kV and 10 kV) with different voltage values, and the other connected to earth, or more than three. This includes the use of several electrodes. It is preferable that one electrode is a nozzle and the other electrode is a collecting electrode.
- the applied electrostatic potential is preferably 3 to 100 kV, more preferably 5 to 50 kV, and even more preferably 5 to 30 kV.
- the dope contains a biocompatible polymer and a solvent.
- the biocompatible polymer is as described above.
- the concentration of the biocompatible polymer in the mold is preferably 1 to 30% by weight, more preferably 2 to 20% by weight. If the concentration of the biocompatible polymer is lower than 1% by weight, it is not preferable because the concentration is too low to form fibers. On the other hand, if it is higher than 30% by weight, the diameter of the resulting fiber is unfavorable.
- the solvent is preferably a substance that dissolves the biocompatible polymer, has a boiling point of 200 ° C. or less at normal pressure, and is a liquid at room temperature.
- the solvent include methylene chloride, chloroform, acetone, methanol, ethanol, propanol, isopropanol, toluene, tetrahydrofuran, 1, 1, 1, 3, 3, 3, 3-hexafluoroisopropyl.
- Examples include propanol, water, 1,4-dioxane, carbon tetrachloride, cyclohexane, cyclohexanone, N, N-dimethylformamide, and acetonitrile.
- methylene chloride, chloroform, and acetone are particularly preferable from the viewpoint of solubility of biocompatible polymers, particularly aliphatic polyesters.
- These solvents may be used alone, or a plurality of solvents may be combined. In the present invention, other solvents may be used in combination as long as the object is not impaired.
- the nozzle diameter is preferably 0.6 to 1.5 mm.
- several nozzles can be used to increase the production rate of the fibrous material.
- the discharge can be performed by extruding the dope with a syringe having a piston such as a syringe.
- a tube having a fine hole (nozzle) at the tip may also be used.
- the dope is pulled by the electrostatic potential difference and threaded toward the electrode.
- the fiber includes not only the state where the solvent is distilled off but also the state where the solvent is still contained. It is preferable to use an electrostatic eliminator between the nozzle and the electrode.
- An electrostatic removal device is a device that disperses the air in the air by applying ion air to the fiber to maintain a uniform ion balance and relaxing the charged state of the fiber before reaching the electrode. By using this device, the thickness of the roll can be increased. By increasing the thickness of the roll, a scaffold material having a large diameter can be obtained.
- the second step is a step of winding and depositing the obtained fiber around a rotating winding shaft to obtain a roll in which the fiber is oriented in a plane parallel to the winding shaft.
- the fiber is deposited around the take-up shaft of the take-up device between the nozzle and the collecting electrode.
- the winding shaft may be cylindrical or prismatic.
- the average apparent density of the scaffold material depends on the number of revolutions of the winding shaft, it is possible to obtain a scaffold material having a desired average apparent density by controlling the number of revolutions of the winding shaft. Specifically, when the rotational speed is high, the average apparent density of the obtained scaffold material is high. On the other hand, when the rotational speed is low, the average apparent density of the obtained scaffold material is low.
- the rotation speed of the winding shaft is preferably :! To 1000 times / min, more preferably 5 to 200 times Z min.
- the resulting roll is substantially oriented with respect to a plane parallel to the winding axis.
- the shape of the roll may be any shape such as a columnar shape or a spindle shape.
- the heat treatment temperature is preferably 40 to 90 ° C.
- FIGS. Fig. 1 shows an example using a syringe
- Fig. 2 shows an example using a thin tube-like dispenser.
- the syringe (2) fills the syringe holding tank (3) of the syringe having the nozzle (1).
- a voltage is applied to the nozzle (1) by a high voltage generator (6), and an electrostatic field is formed between the positive electrode (4) and the negative electrode (5).
- the dope (2) is pushed out of the nozzle (1), the charged dopant moves in the electrostatic field toward the negative electrode (5), forming a fiber.
- the fiber can be formed by the method shown in FIG.
- the nozzle (2) is filled into a nozzle holding tank (3) of a thin tubular discharger having a nozzle (1).
- a positive electrode (4) is inserted into the dope holding tank (3), and a voltage is applied by a high voltage generator (6) to form an electrostatic field with the negative electrode (5).
- the distance between the nozzle (1) at the tip of the discharger and the negative electrode (5) is adjusted, the charged dope is discharged from the nozzle (1) and moves in the electrostatic field toward the negative electrode (5).
- a fiber is formed.
- the fiber is wound on a winding device (7) in front of the negative electrode (5).
- the solvent evaporates to form fibers.
- the solvent completely evaporates until it is collected by the winder (7), but if the solvent is insufficiently evaporated, it may be spun under reduced pressure conditions.
- the spinning temperature is a force that depends on the evaporation behavior of the solvent and the viscosity of the spinning solution. Usually, it is 0-50 ° C.
- Figures 3 and 4 are examples of installing the static eliminator (8).
- An electrostatic removal device (8) is installed between the nozzle (1) and the negative electrode (5) to perform spinning, and the fiber can be collected by the winding device (7).
- the third step is a step of cutting a three-dimensional structure from the obtained roll.
- the 3D structure can be pierced as shown in Fig. 5 using, for example, a cylindrical punch.
- FIG. 5 it is preferable to penetrate the height direction of the three-dimensional structure and the fiber orientation direction in parallel (10). Further, it is preferable that the three-dimensional structure is perforated so that the height direction of the three-dimensional structure is perpendicular to the fiber orientation direction (12).
- the scaffold material (10) is superior in compressive strength to the scaffold material (12). Differentiation and proliferation of cells>
- Cells can be differentiated and proliferated using the scaffold material of the present invention. Differentiation and proliferation of cells can be performed in vitro or in vivo. In vitro, they can be used as a culture substrate for differentiating and proliferating cells. In vivo, the scaffold material of the present invention can be used as a prosthetic material. In particular, the living tissue can be regenerated by embedding the scaffold material of the present invention in the affected area. Alternatively, a material obtained by culturing cells on the footpad material of the present invention in vitro may be embedded in the affected area as a prosthetic material. Examples of the living tissue include osteochondral tissue. Example
- Rat mesenchymal stem cells manufactured by Dainippon Sumitomo Pharma Co., Ltd.
- MEM Minimum Essential Medium 3 ⁇ 4 FBS (Fetal Bovine Serum), PBS (Phosphate-buff erd Saline), Antibiotic-Antimycotic,
- a cylindrical roll made of an aggregate of fibers was obtained by an electrostatic spinning method.
- the inner diameter of the nozzle (1) is 1.3 mm.
- the distance from the nozzle (1) to the winding device (7) was 20 cm, and the distance from the nozzle (1) to the static eliminator (8) was 35 cm.
- the applied voltage was 15 kV.
- a winding device (7) and an electrostatic removal device (8) manufactured by Kasuga Electric Co., Ltd. were installed between the nozzle (1) and the negative electrode (5).
- the positive electrode (4) was inserted into the dope holding tank (3).
- the rotation speed of the winding device (7) was set to 100 rpm.
- a dope was placed in the dope holding tank (3), the distance between the nozzle (1) and the negative electrode (5) was adjusted, and the fibers were discharged from the nozzle (1). Discharging was continued for 120 minutes, and a winding cylindrical roll was obtained with a winding device (7) that rotates the fiber. The roll was placed in a thermostat and kept at 80 ° C for 10 minutes for heat treatment.
- a cylindrical scaffold material having a diameter of 5 mm and a height of 5 mm as shown in 10 in FIG. 5 was cut out using a biopsy trepan (manufactured by KAI Industries Co., Ltd.) in the manner shown in FIG.
- the diameter of the fiber was visually observed with a digital microscope (KEYENCE, VHX DIGITAL MICROSCOPE) or with a scanning electron microscope (manufactured by JEOL Ltd., magnification 200 times). In electron microscope observation, select any 10 lines per field of view. This operation was carried out for 5 fields of view, and an average value of a total of 50 lines was calculated. However, lump-like foreign matters generated in the fiber formation process and those in which the fibers were fused and bundled were excluded from the measurement target.
- the apparent density of the scaffold material was calculated by the following formula.
- the porosity of the scaffold material was calculated by the following formula.
- the compressive strength was measured according to J I SK72 20 for the scaffold material corresponding to (1 0) in FIG. That is, the measurement was performed on a scaffold material in which the fibers are oriented parallel to the height direction of the cylindrical body.
- the test piece was placed between the pressing surfaces of the material testing machine, the center line of the test piece was aligned with the center line of the pressing surface, and it was confirmed that the upper and lower surfaces of the test piece were parallel to the pressing surface.
- a load was applied to the specimen at a constant speed of 10 mmZmin and the measurement was performed up to the compression limit.
- Example 2 Using the same lactic acid monoglycolic acid copolymer as in Example 1, it was prepared to be 10% by weight.
- a cylindrical roll made of an aggregate of fibers was obtained in the same manner as in Example 1 except that the discharge time was 90 minutes and the heat treatment was performed at 70 for 10 minutes.
- Biological evaluation of the scaffold material was performed by the following method. Rat mesenchymal stem cells were cultured in MEM containing 15% FBS and l% Antibiotic-antimycotic for up to 3 passages at 37 ° C and 5 CO 2 .
- the obtained scaffold material is seeded with prepared rat mesenchymal stem cells to 6.0 ⁇ 10 6 cells / cm 3 , and 15% FBS and l% Antibiotic- AnUmycotic, 10 M dexamethasone, 50 yM L - at Ascorbic acid 2-phosphate magnesium salts n -hydrate, 1 OmM j6- glycerophosphate disodium n- hydrate ME M in which was added and incubated 12 days at 37 ° C, 5% C0 2 incubator. The medium was changed 3 times a week.
- the footpad material was taken out on the 1st, 6th, and 12th days of culture, and the amount of DNA and histological evaluation were performed by the following methods.
- the amount of DNA was determined according to the measurement manual of Pico Green (registered trademark) ds DNA Quantitation Kit.
- the sample to be measured was frozen and thawed three times with 0.2% Triton-X100, and then ultrasonically disrupted to obtain a cell suspension, from which an extract was prepared.
- 9 Place a measurement sample that has been treated with 10 O enzyme in a 6-well microplate, add 100 1 of PicoGreen (registered trademark) ds DNAQuanUtation Reagent diluted 200-fold with ⁇ ( ⁇ 7.5), excitation light 485 nm, Fluorescence was measured at a wavelength of 535 nm.
- a calibration curve was created from the values of the standard DNA solution, and the DNA amount of the measurement sample was calculated based on it. The results are shown in Table 2.
- the amount of DNA is proportional to the number of cells grown To do.
- the scaffold material was previously soaked in 10% formaldehyde at the time of sampling. Before staining, wash the scaffold material with distilled water, soak in 100% ethanol twice for 1 hour, 90% ethanol for 1 hour, 70% ethanol
- Washing was carried out with immersion for 1 hour and dilution stepwise. This was washed by immersing it in distilled water for 15 minutes, and then immersed in 0.4% toluidine aqueous solution for 1 minute.
- Table 2 shows the measurement results for the amount of DNA.
- Figures 8 and 9 show dyeing photographs of the scaffold material on day 1 and day 12, respectively. Scaffolding material on the 12th day of culture has higher staining concentration than that on the 1st day, and the staining range has reached the deep part of the scaffolding material, indicating that cell growth and cartilage matrix are well produced. .
- Example 2 The same operation as in Example 2 was repeated to obtain a cylindrical scaffold material having a diameter of 5 mm and a height of 5 mm corresponding to 12 in FIG. Table 1 shows the measured results.
- Figure 10 shows a photomicrograph (200x magnification) of a cross section perpendicular to the bottom surface of the scaffold material corresponding to 12 in Fig. 5. You can see the force S that the fibers are oriented in the plane direction.
- Figure 5 (1
- Figure 1 shows a micrograph (magnification 15x) of the cross section parallel to the bottom surface of the scaffold material corresponding to 2).
- Fig. 13 and Fig. 14 show staining photographs of the scaffold material on day 1 and day 12 of culture.
- the scaffold material on the 12th day of culture has a higher staining concentration than that on the 1st day, and the staining range is deeper than the surface of the scaffold material. And found good cell growth and substrate production.
- the scaffold material of the present invention is excellent in mechanical strength and can withstand weight compression in the initial stage of transplantation. Therefore, it can be used for parts that require mechanical characteristics such as cartilage damage. Since the scaffold material of the present invention is composed of a biocompatible polymer, there is no adverse effect on the living body.
- the footpad material of the present invention has a constant fiber density, allows cells to easily enter, and can quickly supply oxygen and nutrients, and discharge carbon dioxide and waste products. Therefore, the cells can be grown well.
- the scaffold material can be produced by a simple method.
- the fibers obtained by the electrospinning method are deposited on the rotating take-up shaft, so that a fiber deposit having a uniform deposition density in the deposition direction can be obtained.
- a uniform fiber deposit can be obtained with respect to a plane parallel to the winding axis.
- a constant tension is applied to the fiber, and a high-density fiber deposit is obtained.
- cells can be grown well.
- damaged biological tissue can be regenerated well.
- the scaffold material of the present invention is useful as a cell culture substrate in the field of regenerative medicine.
- the scaffold material of the present invention is useful as a prosthetic material, especially a prosthetic material in a site where mechanical properties are important, such as an osteochondral lesion.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002645541A CA2645541A1 (en) | 2006-03-06 | 2007-03-05 | Scaffold material |
US12/281,923 US20090076530A1 (en) | 2006-03-06 | 2007-03-05 | Scaffold |
JP2008503918A JP5119144B2 (ja) | 2006-03-06 | 2007-03-05 | 足場材料 |
AU2007222949A AU2007222949B2 (en) | 2006-03-06 | 2007-03-05 | Scaffold material |
EP07738224A EP1994949A4 (en) | 2006-03-06 | 2007-03-05 | MATERIAL FOR MATRIX |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006-059393 | 2006-03-06 | ||
JP2006059393 | 2006-03-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007102606A1 true WO2007102606A1 (ja) | 2007-09-13 |
Family
ID=38475025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/054739 WO2007102606A1 (ja) | 2006-03-06 | 2007-03-05 | 足場材料 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090076530A1 (ja) |
EP (1) | EP1994949A4 (ja) |
JP (1) | JP5119144B2 (ja) |
KR (1) | KR20080107405A (ja) |
CN (1) | CN101443053A (ja) |
AU (1) | AU2007222949B2 (ja) |
CA (1) | CA2645541A1 (ja) |
WO (1) | WO2007102606A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011125232A (ja) * | 2009-12-15 | 2011-06-30 | Hoya Corp | 細胞培養担体および細胞培養担体の製造方法 |
JP2012192105A (ja) * | 2011-03-17 | 2012-10-11 | Sunstar Inc | 細胞足場材 |
JP2012231743A (ja) * | 2011-05-02 | 2012-11-29 | National Institute For Materials Science | 短繊維足場材料、短繊維−細胞複合凝集塊作製方法及び短繊維−細胞複合凝集塊 |
JP2015504676A (ja) * | 2012-01-13 | 2015-02-16 | ザ ジェネラル ホスピタル コーポレイション | 単離ヒト肺前駆細胞およびその使用 |
WO2015030153A1 (ja) | 2013-08-30 | 2015-03-05 | 日産化学工業株式会社 | 繊維形成用組成物及びその繊維を用いた生体適合材料 |
WO2015093589A1 (ja) | 2013-12-20 | 2015-06-25 | 日産化学工業株式会社 | 繊維、当該繊維の製造用組成物、および当該繊維を含む生体適合材料 |
US11369465B2 (en) | 2013-01-14 | 2022-06-28 | Scripps Health | Tissue array printing |
EP3992276A4 (en) * | 2019-06-27 | 2022-09-07 | Showa Denko Materials Co., Ltd. | CELL SCAFFOLD MATERIAL, SUPPORT AND METHOD FOR CELL CULTURE |
US11497830B2 (en) | 2014-03-14 | 2022-11-15 | Scripps Health | Electrospinning of cartilage and meniscus matrix polymers |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9345486B2 (en) * | 2009-03-16 | 2016-05-24 | University Of Washington | Nanofibrous conduits for nerve regeneration |
JP2014525279A (ja) | 2011-08-12 | 2014-09-29 | カーディアック ペースメイカーズ, インコーポレイテッド | エレクトロスピニング法およびメルトブロー法を用いてデバイスをコーティングする方法 |
WO2013165975A1 (en) * | 2012-04-30 | 2013-11-07 | The Johns Hopkins University | Electro-mechanically stretched micro fibers and methods of use thereof |
US11779682B2 (en) | 2012-04-30 | 2023-10-10 | The Johns Hopkins University | Electro-mechanically stretched micro fibers and methods of use thereof |
WO2015066526A1 (en) * | 2013-10-31 | 2015-05-07 | The Johns Hopkins University | Elecrostretched polymer microfibers for microvasculature development |
US20150025608A1 (en) | 2013-07-22 | 2015-01-22 | Cardiac Pacemakers, Inc. | Lubricious, biocompatible hydrophilic thermoset coating using interpenetrating hydrogel networks |
US10240122B2 (en) | 2014-02-14 | 2019-03-26 | Nissan Chemical Industries, Ltd. | Active-ester-group-containing composition for producing fibers, and cell culture scaffold material using fibers produced from active-ester-group-containing composition |
CA2979982A1 (en) * | 2015-03-17 | 2016-09-22 | President And Fellows Of Harvard College | Automated membrane fabrication system |
US9855415B2 (en) | 2015-07-25 | 2018-01-02 | Cardiac Pacemakers, Inc. | Medical electrical lead with biostable PVDF-based materials |
CN105963753A (zh) * | 2016-06-16 | 2016-09-28 | 湖州科达化工燃料有限公司 | 一种抗感染的医用薄膜 |
BE1024733B1 (fr) | 2016-11-09 | 2018-06-14 | Univercells Sa | Matrice de croissance cellulaire |
CN110325224B (zh) | 2016-12-27 | 2023-01-31 | 波士顿科学国际有限公司 | 用于电纺的可降解支架 |
US20180222145A1 (en) * | 2017-02-07 | 2018-08-09 | Kabushiki Kaisha Toshiba | Fiber-oriented material and method for manufacturing the same |
WO2019079681A1 (en) * | 2017-10-20 | 2019-04-25 | President And Fellows Of Harvard College | METHODS FOR PRODUCING MATURE ADIPOCYTES AND METHODS OF USE |
US20200248122A1 (en) | 2019-02-05 | 2020-08-06 | Corning Incorporated | Packed-bed bioreactor systems and methods of using the same |
US11118151B2 (en) | 2019-11-05 | 2021-09-14 | Corning Incorporated | Fixed bed bioreactor and methods of using the same |
CN111603608B (zh) * | 2020-05-15 | 2021-12-10 | 南通大学 | 普鲁兰多糖-透明质酸-微纤维脊髓支架及其制备方法 |
CN113913805B (zh) * | 2021-10-20 | 2023-08-22 | 中南大学湘雅医院 | 一种冷喷涂改性层及其应用 |
CN114949353B (zh) * | 2022-01-24 | 2023-05-30 | 东华大学 | 一种生物功能差异化的适配肌骨系统修复体及其制备方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5140476A (ja) * | 1974-08-05 | 1976-04-05 | Ici Ltd | |
JP2004520855A (ja) | 2000-03-14 | 2004-07-15 | シモン,ティモシー | 軟骨修復プラグ |
WO2004088024A1 (ja) | 2003-03-31 | 2004-10-14 | Teijin Limited | 不織布およびその製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5681353A (en) * | 1987-07-20 | 1997-10-28 | Regen Biologics, Inc. | Meniscal augmentation device |
ATE412383T1 (de) * | 1997-05-30 | 2008-11-15 | Osteobiologics Inc | Faserverstärkte,poröse,biologisch abbaubare implantatvorrichtung |
US7374777B2 (en) * | 1999-04-14 | 2008-05-20 | Collagen Matrix, Inc. | Oriented biopolymeric membrane for meningeal tissue repair |
-
2007
- 2007-03-05 EP EP07738224A patent/EP1994949A4/en not_active Withdrawn
- 2007-03-05 US US12/281,923 patent/US20090076530A1/en not_active Abandoned
- 2007-03-05 CN CNA2007800164616A patent/CN101443053A/zh active Pending
- 2007-03-05 KR KR1020087021755A patent/KR20080107405A/ko not_active Application Discontinuation
- 2007-03-05 WO PCT/JP2007/054739 patent/WO2007102606A1/ja active Application Filing
- 2007-03-05 JP JP2008503918A patent/JP5119144B2/ja active Active
- 2007-03-05 AU AU2007222949A patent/AU2007222949B2/en not_active Ceased
- 2007-03-05 CA CA002645541A patent/CA2645541A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5140476A (ja) * | 1974-08-05 | 1976-04-05 | Ici Ltd | |
JP2004520855A (ja) | 2000-03-14 | 2004-07-15 | シモン,ティモシー | 軟骨修復プラグ |
WO2004088024A1 (ja) | 2003-03-31 | 2004-10-14 | Teijin Limited | 不織布およびその製造方法 |
Non-Patent Citations (3)
Title |
---|
BOLAND E.D. ET AL.: "Electrospinning of bioresorbable polymers for tissue engineering scaffolds", ACS SYMPOSIUM SERIES, vol. 918, February 2006 (2006-02-01), pages 188 - 204, XP003017642 * |
MATTHEWS J.A. ET AL.: "Electrospinning of Collagen Nanofibers", BIOMACROMOLECULES, vol. 3, no. 2, 2002, pages 232 - 238, XP003005525 * |
See also references of EP1994949A4 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011125232A (ja) * | 2009-12-15 | 2011-06-30 | Hoya Corp | 細胞培養担体および細胞培養担体の製造方法 |
JP2012192105A (ja) * | 2011-03-17 | 2012-10-11 | Sunstar Inc | 細胞足場材 |
JP2012231743A (ja) * | 2011-05-02 | 2012-11-29 | National Institute For Materials Science | 短繊維足場材料、短繊維−細胞複合凝集塊作製方法及び短繊維−細胞複合凝集塊 |
JP2015504676A (ja) * | 2012-01-13 | 2015-02-16 | ザ ジェネラル ホスピタル コーポレイション | 単離ヒト肺前駆細胞およびその使用 |
JP2018198614A (ja) * | 2012-01-13 | 2018-12-20 | ザ ジェネラル ホスピタル コーポレイション | 単離ヒト肺前駆細胞およびその使用 |
US11369465B2 (en) | 2013-01-14 | 2022-06-28 | Scripps Health | Tissue array printing |
WO2015030153A1 (ja) | 2013-08-30 | 2015-03-05 | 日産化学工業株式会社 | 繊維形成用組成物及びその繊維を用いた生体適合材料 |
US9957644B2 (en) | 2013-08-30 | 2018-05-01 | Nissan Chemical Industries, Ltd. | Fiber-forming composition and bio-compatible material using said fiber |
WO2015093589A1 (ja) | 2013-12-20 | 2015-06-25 | 日産化学工業株式会社 | 繊維、当該繊維の製造用組成物、および当該繊維を含む生体適合材料 |
US11497830B2 (en) | 2014-03-14 | 2022-11-15 | Scripps Health | Electrospinning of cartilage and meniscus matrix polymers |
EP3992276A4 (en) * | 2019-06-27 | 2022-09-07 | Showa Denko Materials Co., Ltd. | CELL SCAFFOLD MATERIAL, SUPPORT AND METHOD FOR CELL CULTURE |
Also Published As
Publication number | Publication date |
---|---|
JP5119144B2 (ja) | 2013-01-16 |
KR20080107405A (ko) | 2008-12-10 |
AU2007222949B2 (en) | 2011-04-21 |
EP1994949A4 (en) | 2012-07-18 |
CN101443053A (zh) | 2009-05-27 |
CA2645541A1 (en) | 2007-09-13 |
JPWO2007102606A1 (ja) | 2009-07-23 |
AU2007222949A1 (en) | 2007-09-13 |
US20090076530A1 (en) | 2009-03-19 |
EP1994949A1 (en) | 2008-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5119144B2 (ja) | 足場材料 | |
Zhang et al. | Electrospun PDLLA/PLGA composite membranes for potential application in guided tissue regeneration | |
JP4481994B2 (ja) | 生体吸収性多孔体 | |
Moroni et al. | Fiber diameter and texture of electrospun PEOT/PBT scaffolds influence human mesenchymal stem cell proliferation and morphology, and the release of incorporated compounds | |
Sun et al. | Electrospun anisotropic architectures and porous structures for tissue engineering | |
EP1868660B1 (en) | Medical scaffold, methods of fabrication and using thereof | |
Tan et al. | Electrospun vein grafts with high cell infiltration for vascular tissue engineering | |
JP5046651B2 (ja) | 円筒体の製造方法 | |
Skotak et al. | Improved cellular infiltration into nanofibrous electrospun cross-linked gelatin scaffolds templated with micrometer-sized polyethylene glycol fibers | |
Chen et al. | A three-dimensional dual-layer nano/microfibrous structure of electrospun chitosan/poly (d, l-lactide) membrane for the improvement of cytocompatibility | |
JP5010854B2 (ja) | 血管再生材料 | |
WO2008069760A1 (en) | Three-dimensional porous hybrid scaffold and manufacture thereof | |
WO2012006072A2 (en) | Air impedance electrospinning for controlled porosity | |
WO2006022430A1 (ja) | リン脂質を含有する繊維構造体 | |
WO2009150644A2 (en) | Nonwoven structure and method of fabricating the same | |
Ding et al. | Establishment of 3D culture and induction of osteogenic differentiation of pre-osteoblasts using wet-collected aligned scaffolds | |
JP4988221B2 (ja) | 複合材料 | |
EP2878315A1 (en) | Artificial tissue | |
Stodolak-Zych et al. | The membrane with polylactide and hyaluronic fibers for skin substitute | |
JP5038639B2 (ja) | 培養人工骨 | |
US20230002935A1 (en) | Electrospinning collector for the production of three-dimensional electrospun constructs | |
O'Connor | Electrospinning of tissue engineered blood vessel scaffolds utilising multimodal fibre distributions and dynamic liquid collected yarns | |
Qi et al. | Biomimic tubulose scaffolds with multilayer prepared by electrospinning for tissue engineering | |
Shanmugasundaram et al. | The contribution of electrospinning to tissue engineering and related fields | |
Tahmasebi et al. | BIOCOMPATIBILITY ASSESSMENT OF ELECTROSPUN AND SOLVENT-CAST POLY (Ε-CAPROLACTONE) SUBSTRATA |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2008503918 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007222949 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12281923 Country of ref document: US Ref document number: 2645541 Country of ref document: CA Ref document number: 1020087021755 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2007222949 Country of ref document: AU Date of ref document: 20070305 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007738224 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780016461.6 Country of ref document: CN |